Pharmabiz

BPL Medical Technologies unveils new-gen Glucose Meter as home testing demand rises in India

BPL Medical Technologies unveils new-gen Glucose Meter as home testing demand rises in India: Our Bureau, Bengaluru Tuesday, April 28, 2026, 12:45 Hrs [IST] BPL Medical Technologi ...
Pharmabiz

Emversity and Motherhood Hospitals to launch co-branded certification programme in Maternal and Newborn Care

Emversity and Motherhood Hospitals to launch co-branded certification programme in Maternal and Newborn Care: Our Bureau, Bengaluru Tuesday, April 28, 2026, 12:30 Hrs [IST] Emvers ...
Pharmabiz

Pune Eyecon 2026 brings together domestic and global ophthalmologists to discuss retinal care advancements

Pune Eyecon 2026 brings together domestic and global ophthalmologists to discuss retinal care advancements: Our Bureau, Bengaluru Tuesday, April 28, 2026, 11:30 Hrs [IST] NIO Supe ...
Pharmabiz

GSK subsidiary, TESARO provides update on AnaptysBio litigation

GSK subsidiary, TESARO provides update on AnaptysBio litigation: London, UK Tuesday, April 28, 2026, 12:00 Hrs [IST] GSK plc subsidiary, TESARO, Inc., confirms that the Delaware C ...
Pharmabiz

Apollo Hospitals strengthens India’s next-gen healthcare infrastructure with its 76th unit

Apollo Hospitals strengthens India’s next-gen healthcare infrastructure with its 76th unit: Our Bureau, Bengaluru Tuesday, April 28, 2026, 12:15 Hrs [IST] Apollo Hospitals Group ...
Pharmabiz

Fortis Gurugram unveils ‘Genomic 360 Wellness Programme’ to transform individual health outcomes

Fortis Gurugram unveils ‘Genomic 360 Wellness Programme’ to transform individual health outcomes: Our Bureau, Bengaluru Tuesday, April 28, 2026, 11:45 Hrs [IST] Fortis Memoria ...
Pharmabiz

CDAC Bengaluru sets up Centre for IoT in SRM Institute of Science and Technology

CDAC Bengaluru sets up Centre for IoT in SRM Institute of Science and Technology: Our Bureau, Bengaluru Tuesday, April 28, 2026, 11:15 Hrs [IST] SRM Institute of Science and Techn ...
Pharmabiz

European Commission approves Novartis Rhapsido for CSU in adult patients with inadequate response to H1-antihistamine treatment

Novartis announced that the European Commission (EC) approved Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1-antihistamine treatment.
Pharmabiz

AstraZeneca’s Saphnelo approved in US for subcutaneous self-administration as a new autoinjector to treat systemic lupus erythematosus

AstraZeneca’s Saphnelo approved in US for subcutaneous self-administration as a new autoinjector to treat systemic lupus erythematosus: Cambridge, UK Tuesday, April 28, 2026, 10 ...
Pharmabiz

Tier-2 & semi-urban regions are emerging as critical drivers of digital health adoption: Anurag Yadav

Tier-2 & semi-urban regions are emerging as critical drivers of digital health adoption: Anurag Yadav: Nandita Vijayasimha, Bengaluru Tuesday, April 28, 2026, 08:00 Hrs [IST] Indi ...
Pharmabiz

Pharma leaders hail Jan Vishwas Act’s ‘trust-based’ shift while red-flagging implementation hurdles

Pharma leaders hail Jan Vishwas Act’s ‘trust-based’ shift while red-flagging implementation hurdles: Peethaambaran Kunnathoor, Chennai Tuesday, April 28, 2026, 08:00 Hrs [IS ...
Pharmabiz

Further examination required on exemption of Biodeal's Midazolam nasal spray from DPCO: MDC

Further examination required on exemption of Biodeal's Midazolam nasal spray from DPCO: MDC: Gireesh Babu, New Delhi Tuesday, April 28, 2026, 08:00 Hrs [IST] The Multidisciplinary ...